Breukelen, Utrecht, Netherlands
Bart Wuurman is an accomplished biotech CEO and entrepreneur with strong experience in strategic leadership, innovative drug development, biotech financing and business development & licensing. As biotech executive, he was instrumental to the profitable exits of two biotech companies: Lanthio Pharma and Antisoma. He is passionate about bringing commercial focus in an academic environment to translate science into the development of innovative drugs for patients that need them. During 34 years with innovative R&D based life sciences companies, Bart has built a broad experience in pharmaceutical product development in many therapeutic areas, including immuno-oncology, inflammatory and ageing related diseases.
Hirundo Biosciences is a fully owned subsidiary of Gedeon Richter, tasked with Female Health product R&D
BlueWave provides Executive Management support to bio-pharmaceutical companies and can help with Fundraising and Business Development and Licensing. It furthermore supports Life-Science investors with Investment Sourcing, Pre-investment Due Diligence and by taking Non-Executive Board positions in portfolio companies.
Apaxen, a Belgian biotech company focused on developing innovative treatments for chronic inflammatory and fibrotic diseases. It's lead product MFC-1040 targets Macrophage Migration Inhibitory Factor (MIF) and was developed up to First-In-Human clinical testing.
Hercules was created by DDF Ventures as a spin-off from Boston University, developing novel anti-cancer and anti-viral drugs based on selective immune modulation. Hercules’ drugs are small molecule inhibitors of the Aryl Hydrocarbon Receptor and are in early stages of pre-clinical development.
Lyramid is engaged in the development of First-In-Class antibody based drugs for treatment of chronic inflammatory diseases and auto-immune diseases. For this purpose Lyramid is targeting midkine. Lyramid was acquired by Roquefort Therapeutics.